Ebbert Jon O, Wyatt Kirk D, Hays J Taylor, Klee Eric W, Hurt Richard D
Mayo Clinic College of Medicine, Rochester, MN, USA.
Patient Prefer Adherence. 2010 Oct 5;4:355-62. doi: 10.2147/ppa.s10620.
Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a public health priority. Patients achieve the greatest success when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of tobacco dependence. Varenicline is efficacious and cost-effective. Smoking relapse and adverse treatment-related side effects may decrease medication adherence and patient satisfaction with varenicline. In the clinical setting, varenicline treatment can be optimized by reducing doses in patients who experience intolerable side effects, increasing the dose in partial responders, and providing long-term maintenance therapy for relapse prevention.
在美国,吸烟是可预防的发病和死亡的首要原因,降低吸烟率是公共卫生的重点。当戒烟尝试包括行为疗法和药物疗法相结合时,患者取得的成功最大。伐尼克兰是治疗烟草依赖的药物治疗手段中的最新药物。伐尼克兰有效且具有成本效益。吸烟复发和与治疗相关的不良副作用可能会降低患者对伐尼克兰的依从性和满意度。在临床环境中,对于出现无法耐受副作用的患者减少剂量、对部分反应者增加剂量以及提供预防复发的长期维持治疗,可以优化伐尼克兰治疗。